These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21572345)

  • 1. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Hartmann C; Weinel P; Schmid H; Grigull L; Sander A; Linderkamp C; Welte K; Reinhardt D
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):344-9. PubMed ID: 21572345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
    Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
    Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
    Geoerger B; Chisholm J; Le Deley MC; Gentet JC; Zwaan CM; Dias N; Jaspan T; Mc Hugh K; Couanet D; Hain S; Devos A; Riccardi R; Cesare C; Boos J; Frappaz D; Leblond P; Aerts I; Vassal G;
    Eur J Cancer; 2011 Jan; 47(2):230-8. PubMed ID: 20943374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
    Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
    de Lima Lopes G; Chiappori A; Simon G; Haura E; Sullivan D; Antonia S; Langevin M; Lush R; Rocha-Lima CM
    Cancer; 2007 Apr; 109(7):1413-9. PubMed ID: 17326096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
    Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
    Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
    Agelaki S; Syrigos K; Christophylakis C; Boukovinas J; Varthalitis J; Pavlakou G; Athanasiadis A; Kouroussis C; Vardakis N; Maltezakis G; Milaki G; Georgoulias V;
    Oncology; 2004; 66(3):192-6. PubMed ID: 15218309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
    Massimino M; Casanova M; Polastri D; Biassoni V; Modena P; Pecori E; Schiavello E; De Pava MV; Indini A; Rampini P; Bauer D; Catania S; Podda M; Gandola L
    Childs Nerv Syst; 2013 Jul; 29(7):1107-12. PubMed ID: 23595805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
    Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
    J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
    Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
    Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
    Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-based combination treatment of pancreatic cancer.
    Heinemann V
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.